D.E. Shaw & Co
ELDN icon

D.E. Shaw & Co’s Eledon Pharmaceuticals ELDN Stock Holding History

D.E. Shaw & Co’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-694
Closed -$58K – 3806
2018
Q3 		$58K Sell
694
-81
-10% -$8.27K ﹤0.01% 3652
2018
Q2 		$98K Sell
775
-52
-6% -$5.37K ﹤0.01% 3618
2018
Q1 		$72K Sell
827
-44
-5% -$3.24K ﹤0.01% 3410
2017
Q4 		$61K Hold
871
– – ﹤0.01% 3526
2017
Q3 		$82K Hold
871
– – ﹤0.01% 3379
2017
Q2 		$92K Sell
871
-177
-17% -$18K ﹤0.01% 3272
2017
Q1 		$142K Sell
1,048
-211
-17% -$31K ﹤0.01% 3167
2016
Q4 		$199K Buy
1,259
+954
+313% +$183K ﹤0.01% 3269
2016
Q3 		$76K Buy
+305
New +$112K ﹤0.01% 3305
2016
Q1 		– Sell
-112
Closed -$158K – 3509
2015
Q4 		$158K Buy
+112
New +$195K ﹤0.01% 3613

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CSPIA
Cary Street Partners Investment Advisory Richmond, Virginia $494M AUM 27.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's ELDN Position: Q4 2018 in Review

D.E. Shaw & Co sold out of Eledon Pharmaceuticals (ELDN) in Q4 2018, closing a stake of 694 shares — an estimated $58K sold.

D.E. Shaw & Co first reported a position in ELDN in Q4 2015 and held it in 10 quarters. The position peaked at $199K in Q4 2016. 16 funds tracked by Wall St. Rank hold ELDN as of Q4 2018.

  • D.E. Shaw & Co reported no remaining Eledon Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • D.E. Shaw & Co sold 694 Eledon Pharmaceuticals shares in Q4 2018, an estimated $58K.
  • D.E. Shaw & Co first reported a position in Eledon Pharmaceuticals in Q4 2015 and held it in 10 quarters.
  • D.E. Shaw & Co's Eledon Pharmaceuticals position peaked at $199K in Q4 2016.
  • 16 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2018.

Based on D.E. Shaw & Co's 13F filing for Q4 2018, filed 14 Feb 2019.